Thursday, 15 October 2026European Markets

COHERIS Stock Is 23% Up In The Last 10 Sessions

Loading stream...

(vianews) - shares of coheris (cac 40: coh.pa) rose by a staggering 23.44% in 10 sessions from €4.82 to €5.95 at 20:52 est on wednesday, after three successive sessions in a row of gains. cac 40 is rising 1.57% to €7,333.01, after three sequential sessions in a row of gains.

coheris's last close was €5.80, 8.41% above its 52-week high of €5.35.

about coheris

coheris sa provides customer relationship management (crm) and analytics solutions in france and internationally. the company offers data solutions, such as digital and speech intelligence, cyber security, data science, data operating system, data mining and machine learning, and business intelligence and analytics. it also provides crm customer service, sales force, and marketing; and unified commerce, including digital in-store, order management system, e-merchandising and searchandsing, wen-to-store, store management, unified stocks, returns and refunds, and clienteling, as well as product recommendation, seller performance optimization, look book, and digital asset management services. in addition, the company offers merchandising, and e-merchandising and search software; marketing automation; and last mile logistics services. it serves bank and finance, mutual insurance, consumer goods and gics, retail, agrifood, otc and pharmacy, out-of-home consumption, industry, luxury premium, audience, and regalian sectors. the company is based in suresnes, france. coheris sa is as subsidiary of chapsvision.

earnings per share

as for profitability, coheris has a trailing twelve months eps of €0.78.

pe ratio

coheris has a trailing twelve months price to earnings ratio of 7.63. meaning, the purchaser of the share is investing €7.63 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.78%.

more news about coheris (coh.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com